CD19 and leukemia: In 2002, the second-generation of CAR-T cells was developed and proved to be effective in vitro [6] and in 2003, Dr Sadelain demonstrated that the CD19-targeted CAR-T cells could kill leukemia cells in a mouse model [7], which had an enormous impact in the future development of CAR-T therapy.